Immunogenicity and Reactogenicity of a Booster Dose of GlaxoSmithKline Biologicals' GSK2036874A Vaccine in Healthy Toddlers.
Phase of Trial: Phase II
Latest Information Update: 24 May 2017
At a glance
- Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hib-DTP-hepatitis B vaccine; Poliovirus vaccine inactivated
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 15 Dec 2010 Actual patient number is 312 according to ClinicalTrials.gov.
- 10 Dec 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 10 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.